Last reviewed · How we verify
ISOCONAZOLE — Competitive Intelligence Brief
phase 2
isoconazole
Indoleamine 2,3-dioxygenase 1, Steroid 17-alpha-hydroxylase/17,20 lyase
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
ISOCONAZOLE (ISOCONAZOLE). ISOCONAZOLE works by inhibiting the enzyme steroid 17-alpha-hydroxylase/17,20 lyase, which is involved in the production of steroids and other hormones.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ISOCONAZOLE TARGET | ISOCONAZOLE | phase 2 | isoconazole | Indoleamine 2,3-dioxygenase 1, Steroid 17-alpha-hydroxylase/17,20 lyase |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (isoconazole class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ISOCONAZOLE CI watch — RSS
- ISOCONAZOLE CI watch — Atom
- ISOCONAZOLE CI watch — JSON
- ISOCONAZOLE alone — RSS
- Whole isoconazole class — RSS
Cite this brief
Drug Landscape (2026). ISOCONAZOLE — Competitive Intelligence Brief. https://druglandscape.com/ci/isoconazole. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing